Published in Nat Rev Microbiol on November 02, 2009
Escalating Monthly Doses of Tafenoquine in Healthy Volunteers (TQ) | NCT05203744
A major genome region underlying artemisinin resistance in malaria. Science (2012) 6.25
Spiroindolones, a potent compound class for the treatment of malaria. Science (2010) 5.94
Ranking of elimination feasibility between malaria-endemic countries. Lancet (2010) 4.05
Drug resistance. K13-propeller mutations confer artemisinin resistance in Plasmodium falciparum clinical isolates. Science (2014) 3.41
Absence of putative artemisinin resistance mutations among Plasmodium falciparum in Sub-Saharan Africa: a molecular epidemiologic study. J Infect Dis (2014) 3.21
Got ACTs? Availability, price, market share and provider knowledge of anti-malarial medicines in public and private sector outlets in six malaria-endemic countries. Malar J (2011) 2.99
Artemisinin activity against Plasmodium falciparum requires hemoglobin uptake and digestion. Proc Natl Acad Sci U S A (2011) 2.94
Quantitative assessment of Plasmodium falciparum sexual development reveals potent transmission-blocking activity by methylene blue. Proc Natl Acad Sci U S A (2011) 2.83
Plasmodium falciparum clearance rates in response to artesunate in Malian children with malaria: effect of acquired immunity. J Infect Dis (2013) 2.47
Selective and specific inhibition of the plasmodium falciparum lysyl-tRNA synthetase by the fungal secondary metabolite cladosporin. Cell Host Microbe (2012) 2.05
Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potential. J Med Chem (2011) 1.94
Altered temporal response of malaria parasites determines differential sensitivity to artemisinin. Proc Natl Acad Sci U S A (2013) 1.83
Identification of a mutant PfCRT-mediated chloroquine tolerance phenotype in Plasmodium falciparum. PLoS Pathog (2010) 1.71
Inhibition of Plasmepsin V activity demonstrates its essential role in protein export, PfEMP1 display, and survival of malaria parasites. PLoS Biol (2014) 1.68
Recent clinical and molecular insights into emerging artemisinin resistance in Plasmodium falciparum. Curr Opin Infect Dis (2011) 1.68
PfCRT and its role in antimalarial drug resistance. Trends Parasitol (2012) 1.63
How can we identify parasite genes that underlie antimalarial drug resistance? Pharmacogenomics (2011) 1.44
Ex vivo susceptibility of Plasmodium falciparum isolates from Dakar, Senegal, to seven standard anti-malarial drugs. Malar J (2011) 1.40
Drug discovery: Priming the antimalarial pipeline. Nature (2010) 1.40
Identifying apicoplast-targeting antimalarials using high-throughput compatible approaches. FASEB J (2011) 1.31
Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice. J Med Chem (2011) 1.28
Genome scanning of Amazonian Plasmodium falciparum shows subtelomeric instability and clindamycin-resistant parasites. Genome Res (2010) 1.27
Estimated under-five deaths associated with poor-quality antimalarials in sub-Saharan Africa. Am J Trop Med Hyg (2015) 1.18
Investigations into the role of the Plasmodium falciparum SERCA (PfATP6) L263E mutation in artemisinin action and resistance. Antimicrob Agents Chemother (2010) 1.14
Diversity-Oriented Synthesis Yields a Novel Lead for the Treatment of Malaria. ACS Med Chem Lett (2011) 1.12
Plasmodium falciparum parasites are killed by a transition state analogue of purine nucleoside phosphorylase in a primate animal model. PLoS One (2011) 1.10
Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum. Antimicrob Agents Chemother (2010) 1.10
Early variations in plasmodium falciparum dynamics in Nigerian children after treatment with two artemisinin-based combinations: implications on delayed parasite clearance. Malar J (2010) 1.10
Evidence that mutant PfCRT facilitates the transmission to mosquitoes of chloroquine-treated Plasmodium gametocytes. J Infect Dis (2011) 1.10
Eating at the table of another: metabolomics of host-parasite interactions. Cell Host Microbe (2010) 1.08
Genome-wide screen identifies new candidate genes associated with artemisinin susceptibility in Plasmodium falciparum in Kenya. Sci Rep (2013) 1.07
Identification of inhibitors for putative malaria drug targets among novel antimalarial compounds. Mol Biochem Parasitol (2010) 1.06
Target validation: linking target and chemical properties to desired product profile. Curr Top Med Chem (2011) 1.04
Malaria drug resistance: new observations and developments. Essays Biochem (2011) 1.03
Replication of Plasmodium in reticulocytes can occur without hemozoin formation, resulting in chloroquine resistance. J Exp Med (2015) 1.02
In vitro cardiovascular effects of dihydroartemisin-piperaquine combination compared with other antimalarials. Antimicrob Agents Chemother (2012) 1.02
DNA topoisomerases in apicomplexan parasites: promising targets for drug discovery. Proc Biol Sci (2010) 1.02
Modeling within-host effects of drugs on Plasmodium falciparum transmission and prospects for malaria elimination. PLoS Comput Biol (2014) 1.01
Spontaneous mutations in the Plasmodium falciparum sarcoplasmic/ endoplasmic reticulum Ca2+-ATPase (PfATP6) gene among geographically widespread parasite populations unexposed to artemisinin-based combination therapies. Antimicrob Agents Chemother (2010) 1.01
Fingerprinting the substrate specificity of M1 and M17 aminopeptidases of human malaria, Plasmodium falciparum. PLoS One (2012) 1.00
Anti-plasmodial polyvalent interactions in Artemisia annua L. aqueous extract--possible synergistic and resistance mechanisms. PLoS One (2013) 1.00
Impact of antimalarial treatment and chemoprevention on the drug sensitivity of malaria parasites isolated from ugandan children. Antimicrob Agents Chemother (2015) 1.00
In vivo and in vitro antimalarial properties of azithromycin-chloroquine combinations that include the resistance reversal agent amlodipine. Antimicrob Agents Chemother (2011) 0.99
Use of the atmospheric generators for capnophilic bacteria Genbag-CO2 for the evaluation of in vitro Plasmodium falciparum susceptibility to standard anti-malarial drugs. Malar J (2011) 0.98
Fluorine modulates species selectivity in the triazolopyrimidine class of Plasmodium falciparum dihydroorotate dehydrogenase inhibitors. J Med Chem (2014) 0.96
Drug resistance genomics of the antimalarial drug artemisinin. Genome Biol (2014) 0.95
In vitro-reduced susceptibility to artemether in P. falciparum and its association with polymorphisms on transporter genes. J Infect Dis (2012) 0.94
Ex vivo activity of the ACT new components pyronaridine and piperaquine in comparison with conventional ACT drugs against isolates of Plasmodium falciparum. Malar J (2012) 0.94
Artemisinin Action and Resistance in Plasmodium falciparum. Trends Parasitol (2016) 0.93
Spatial and temporal mapping of the PfEMP1 export pathway in Plasmodium falciparum. Cell Microbiol (2013) 0.93
Synthesis of artemiside and its effects in combination with conventional drugs against severe murine malaria. Antimicrob Agents Chemother (2011) 0.92
Absence of association between pyronaridine in vitro responses and polymorphisms in genes involved in quinoline resistance in Plasmodium falciparum. Malar J (2010) 0.91
A Cost-Effectiveness Analysis of Plasmodium falciparum Malaria Elimination in Hainan Province, 2002-2012. Am J Trop Med Hyg (2015) 0.91
Balancing drug resistance and growth rates via compensatory mutations in the Plasmodium falciparum chloroquine resistance transporter. Mol Microbiol (2015) 0.90
The antimalarial amodiaquine causes autophagic-lysosomal and proliferative blockade sensitizing human melanoma cells to starvation- and chemotherapy-induced cell death. Autophagy (2013) 0.89
Transmembrane segment 11 appears to line the purine permeation pathway of the Plasmodium falciparum equilibrative nucleoside transporter 1 (PfENT1). J Biol Chem (2010) 0.89
It Is Not Just Folklore: The Aqueous Extract of Mung Bean Coat Is Protective against Sepsis. Evid Based Complement Alternat Med (2012) 0.89
Mechanisms of hematin crystallization and inhibition by the antimalarial drug chloroquine. Proc Natl Acad Sci U S A (2015) 0.89
Lead optimization of 3-carboxyl-4(1H)-quinolones to deliver orally bioavailable antimalarials. J Med Chem (2012) 0.88
Cure of hookworm infection with a cysteine protease inhibitor. PLoS Negl Trop Dis (2012) 0.88
Ex vivo responses of Plasmodium falciparum clinical isolates to conventional and new antimalarial drugs in Niger. Antimicrob Agents Chemother (2013) 0.88
CRISPR-Cas9-modified pfmdr1 protects Plasmodium falciparum asexual blood stages and gametocytes against a class of piperazine-containing compounds but potentiates artemisinin-based combination therapy partner drugs. Mol Microbiol (2016) 0.88
The burden of malaria in post-emergency refugee sites: A retrospective study. Confl Health (2011) 0.87
Synthesis of five- and six-membered cyclic organic peroxides: Key transformations into peroxide ring-retaining products. Beilstein J Org Chem (2014) 0.87
Relationship between treatment-seeking behaviour and artemisinin drug quality in Ghana. Malar J (2012) 0.86
Artemisinin and its derivatives can significantly inhibit lung tumorigenesis and tumor metastasis through Wnt/β-catenin signaling. Oncotarget (2016) 0.85
Cysteamine, the molecule used to treat cystinosis, potentiates the antimalarial efficacy of artemisinin. Antimicrob Agents Chemother (2010) 0.84
Choline analogues in malaria chemotherapy. Curr Pharm Des (2012) 0.83
Metabolic analyses elucidate non-trivial gene targets for amplifying dihydroartemisinic acid production in yeast. Front Microbiol (2013) 0.83
In vitro antimicrobial activity on clinical microbial strains and antioxidant properties of Artemisia parviflora. Ann Clin Microbiol Antimicrob (2012) 0.83
Do frontline health care providers know enough about artemisinin-based combination therapy to rationally treat malaria? A cross-sectional survey in Gezira State, Sudan. Malar J (2015) 0.82
In vitro and in vivo activity of solithromycin (CEM-101) against Plasmodium species. Antimicrob Agents Chemother (2011) 0.81
Strategic use of antimalarial drugs that block falciparum malaria parasite transmission to mosquitoes to achieve local malaria elimination. Parasitol Res (2014) 0.81
Combinatorial Genetic Modeling of pfcrt-Mediated Drug Resistance Evolution in Plasmodium falciparum. Mol Biol Evol (2016) 0.81
Real-time imaging of the intracellular glutathione redox potential in the malaria parasite Plasmodium falciparum. PLoS Pathog (2013) 0.80
Treating uncomplicated malaria in children: comparing artemisinin-based combination therapies. Curr Opin Pediatr (2010) 0.80
Combinatorial strategies for combating invasive fungal infections. Virulence (2016) 0.80
Epidemiology: resistance mapping in malaria. Nature (2013) 0.79
Evidence for pyronaridine as a highly effective partner drug for treatment of artemisinin-resistant malaria in a rodent model. Antimicrob Agents Chemother (2013) 0.79
Amodiaquine-Artesunate versus Artemether-Lumefantrine against Uncomplicated Malaria in Children Less Than 14 Years in Ngaoundere, North Cameroon: Efficacy, Safety, and Baseline Drug Resistant Mutations in pfcrt, pfmdr1, and pfdhfr Genes. Malar Res Treat (2013) 0.79
Design, Synthesis, and Antiplasmodial Activity of Hybrid Compounds Based on (2R,3S)-N-Benzoyl-3-phenylisoserine. ACS Med Chem Lett (2013) 0.79
Malaria-infected mice live until at least day 30 after a new artemisinin-derived thioacetal thiocarbonate combined with mefloquine are administered together in a single, low, oral dose. J Med Chem (2012) 0.79
Efficacy and safety of dihydroartemisinin-piperaquine for treatment of Plasmodium vivax malaria in endemic countries: meta-analysis of randomized controlled studies. PLoS One (2013) 0.79
Discovery of a novel and conserved Plasmodium falciparum exported protein that is important for adhesion of PfEMP1 at the surface of infected erythrocytes. Cell Microbiol (2015) 0.79
Specific antibodies to Anopheles gSG6-P1 salivary peptide to assess early childhood exposure to malaria vector bites. Malar J (2015) 0.78
Identification and optimization of an aminoalcohol-carbazole series with antimalarial properties. ACS Med Chem Lett (2013) 0.78
No evidence of decreased artemisinin efficacy in a high-transmission malaria setting in Mali. Am J Trop Med Hyg (2012) 0.78
Little Polymorphism at the K13 Propeller Locus in Worldwide Plasmodium falciparum Populations Prior to the Introduction of Artemisinin Combination Therapies. Antimicrob Agents Chemother (2016) 0.78
Antimalarials inhibit hematin crystallization by unique drug-surface site interactions. Proc Natl Acad Sci U S A (2017) 0.78
Investigating preferences for mosquito-control technologies in Mozambique with latent class analysis. Malar J (2011) 0.77
Does the Use of Dihydroartemisinin-Piperaquine in Treating Patients with Uncomplicated falciparum Malaria Reduce the Risk for Recurrent New falciparum Infection More Than Artemether-Lumefantrine? Malar Res Treat (2014) 0.77
Chloroquine interference with hemoglobin endocytic trafficking suppresses adaptive heme and iron homeostasis in macrophages: the paradox of an antimalarial agent. Oxid Med Cell Longev (2013) 0.77
Statistical experimental design guided optimization of a one-pot biphasic multienzyme total synthesis of amorpha-4,11-diene. PLoS One (2013) 0.77
The X-ray structure of Plasmodium falciparum dihydroorotate dehydrogenase bound to a potent and selective N-phenylbenzamide inhibitor reveals novel binding-site interactions. Acta Crystallogr F Struct Biol Commun (2015) 0.76
Gibberellin biosynthetic inhibitors make human malaria parasite Plasmodium falciparum cells swell and rupture to death. PLoS One (2012) 0.76
A Water-Soluble Polysaccharide from the Fruit Bodies of Bulgaria inquinans (Fries) and Its Anti-Malarial Activity. Evid Based Complement Alternat Med (2011) 0.76
Beauvericin Potentiates Azole Activity via Inhibition of Multidrug Efflux, Blocks Candida albicans Morphogenesis, and Is Effluxed via Yor1 and Circuitry Controlled by Zcf29. Antimicrob Agents Chemother (2016) 0.76
Growth of Large Hematin Crystals in Biomimetic Solutions. Cryst Growth Des (2014) 0.76
Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med (2009) 33.25
The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature (2005) 31.73
Production of the antimalarial drug precursor artemisinic acid in engineered yeast. Nature (2006) 13.86
Genetic diversity and chloroquine selective sweeps in Plasmodium falciparum. Nature (2002) 12.09
Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol Cell (2000) 10.72
Amplification-free Illumina sequencing-library preparation facilitates improved mapping and assembly of (G+C)-biased genomes. Nat Methods (2009) 10.41
Vivax malaria: neglected and not benign. Am J Trop Med Hyg (2007) 10.16
Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet (2004) 9.68
A molecular marker for chloroquine-resistant falciparum malaria. N Engl J Med (2001) 9.18
Intercontinental spread of pyrimethamine-resistant malaria. Science (2004) 8.73
The burden of malaria in pregnancy in malaria-endemic areas. Am J Trop Med Hyg (2001) 8.60
Resistance of Plasmodium falciparum field isolates to in-vitro artemether and point mutations of the SERCA-type PfATPase6. Lancet (2005) 8.30
Qinghaosu (artemisinin): the price of success. Science (2008) 8.25
Conquering the intolerable burden of malaria: what's new, what's needed: a summary. Am J Trop Med Hyg (2004) 8.13
Artemisinins target the SERCA of Plasmodium falciparum. Nature (2003) 7.72
Return of chloroquine antimalarial efficacy in Malawi. N Engl J Med (2006) 7.70
Epidemiology of drug-resistant malaria. Lancet Infect Dis (2002) 7.59
Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study. Lancet (2000) 7.06
Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia. PLoS Med (2008) 6.61
Measuring malaria endemicity from intense to interrupted transmission. Lancet Infect Dis (2008) 6.53
In vivo selection of Plasmodium falciparum pfmdr1 86N coding alleles by artemether-lumefantrine (Coartem). J Infect Dis (2005) 6.13
Immunity to malaria: more questions than answers. Nat Immunol (2008) 5.71
Annual Plasmodium falciparum entomological inoculation rates (EIR) across Africa: literature survey, Internet access and review. Trans R Soc Trop Med Hyg (2000) 5.45
Variations in frequencies of drug resistance in Plasmodium falciparum. Proc Natl Acad Sci U S A (1997) 5.07
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial. Lancet (2001) 4.86
Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. Lancet (2007) 4.85
Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. Antimicrob Agents Chemother (2000) 4.77
Antimalarial drug quality in the most severely malarious parts of Africa - a six country study. PLoS One (2008) 4.76
Chloroquine-resistant malaria. J Infect Dis (2001) 4.58
Pfmdr1 and in vivo resistance to artesunate-mefloquine in falciparum malaria on the Cambodian-Thai border. Am J Trop Med Hyg (2007) 4.51
The structure of malaria pigment beta-haematin. Nature (2000) 4.24
Decreasing pfmdr1 copy number in plasmodium falciparum malaria heightens susceptibility to mefloquine, lumefantrine, halofantrine, quinine, and artemisinin. J Infect Dis (2006) 4.21
Treatment of multidrug-resistant Plasmodium falciparum malaria with 3-day artesunate-mefloquine combination. J Infect Dis (1994) 4.17
Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria. Clin Infect Dis (2006) 4.14
Randomised trial of pyronaridine versus chloroquine for acute uncomplicated falciparum malaria in Africa. Lancet (1996) 4.13
Mechanisms of resistance of malaria parasites to antifolates. Pharmacol Rev (2005) 4.04
A new global malaria eradication strategy. Lancet (2008) 4.01
A collaborative epidemiological investigation into the criminal fake artesunate trade in South East Asia. PLoS Med (2008) 3.97
Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in falciparum malaria: an open-label randomised comparison. Lancet (2006) 3.90
Malaria in pregnancy: pathogenesis and immunity. Lancet Infect Dis (2007) 3.88
Combination therapy for malaria in Africa: hype or hope? Bull World Health Organ (2003) 3.83
Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial. Lancet (2004) 3.72
Artemisinin-resistant malaria in Asia. N Engl J Med (2009) 3.58
Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients. Br J Clin Pharmacol (1998) 3.53
The risk of a mosquito-borne infection in a heterogeneous environment. PLoS Biol (2004) 3.46
Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria. Clin Infect Dis (2007) 3.27
Intermittent preventive treatment for malaria control administered at the time of routine vaccinations in Mozambican infants: a randomized, placebo-controlled trial. J Infect Dis (2006) 3.17
A randomized, controlled study of a simple, once-daily regimen of dihydroartemisinin-piperaquine for the treatment of uncomplicated, multidrug-resistant falciparum malaria. Clin Infect Dis (2005) 3.15
Piperaquine: a resurgent antimalarial drug. Drugs (2005) 2.80
In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with artemether-lumefantrine in Africa. J Infect Dis (2009) 2.80
Selection of Plasmodium falciparum pfmdr1 alleles following therapy with artemether-lumefantrine in an area of Uganda where malaria is highly endemic. Antimicrob Agents Chemother (2006) 2.74
Does malaria suffer from lack of memory? Immunol Rev (2004) 2.66
A systematic review and meta-analysis of evidence for correlation between molecular markers of parasite resistance and treatment outcome in falciparum malaria. Malar J (2009) 2.64
The Anopheles dirus complex: spatial distribution and environmental drivers. Malar J (2007) 2.43
Human red blood cell polymorphisms and malaria. Curr Opin Microbiol (2006) 2.34
Efficacy and tolerability of four antimalarial combinations in the treatment of uncomplicated Plasmodium falciparum malaria in Senegal. Malar J (2007) 2.26
Use of high-density tiling microarrays to identify mutations globally and elucidate mechanisms of drug resistance in Plasmodium falciparum. Genome Biol (2009) 2.23
Amodiaquine resistant Plasmodium falciparum malaria in vivo is associated with selection of pfcrt 76T and pfmdr1 86Y. Infect Genet Evol (2005) 2.22
Possible modes of action of the artemisinin-type compounds. Trends Parasitol (2001) 2.20
Gene encoding a deubiquitinating enzyme is mutated in artesunate- and chloroquine-resistant rodent malaria parasites. Mol Microbiol (2007) 2.18
The role of pfmdr1 in Plasmodium falciparum tolerance to artemether-lumefantrine in Africa. Trop Med Int Health (2007) 2.17
Malaria parasites can develop stable resistance to artemisinin but lack mutations in candidate genes atp6 (encoding the sarcoplasmic and endoplasmic reticulum Ca2+ ATPase), tctp, mdr1, and cg10. Antimicrob Agents Chemother (2006) 2.16
Transporters involved in resistance to antimalarial drugs. Trends Pharmacol Sci (2006) 2.09
High risk of neutropenia in HIV-infected children following treatment with artesunate plus amodiaquine for uncomplicated malaria in Uganda. Clin Infect Dis (2008) 2.05
Malaria in pregnancy as an indirect cause of infant mortality in sub-Saharan Africa. Trans R Soc Trop Med Hyg (2002) 2.03
High efficacy of two artemisinin-based combinations (artesunate + amodiaquine and artemether + lumefantrine) in Caala, Central Angola. Am J Trop Med Hyg (2006) 1.92
Disruption of a Plasmodium falciparum multidrug resistance-associated protein (PfMRP) alters its fitness and transport of antimalarial drugs and glutathione. J Biol Chem (2008) 1.86
Safety evaluation of fixed combination piperaquine plus dihydroartemisinin (Artekin) in Cambodian children and adults with malaria. Br J Clin Pharmacol (2004) 1.84
Antimalarial activity of mefloquine and qinghaosu. Lancet (1982) 1.81
The antimalarial drug artemisinin alkylates heme in infected mice. Proc Natl Acad Sci U S A (2005) 1.81
Current perspectives on the mechanism of action of artemisinins. Int J Parasitol (2006) 1.80
How antimalarial drug resistance affects post-treatment prophylaxis. Malar J (2008) 1.80
Diversity of the sarco/endoplasmic reticulum Ca(2+)-ATPase orthologue of Plasmodium falciparum (PfATP6). Infect Genet Evol (2008) 1.80
Prevalence of in vitro resistance to eleven standard or new antimalarial drugs among Plasmodium falciparum isolates from Pointe-Noire, Republic of the Congo. J Clin Microbiol (2006) 1.74
Dichlorodiphenyltrichloroethane (DDT) for indoor residual spraying in Africa: how can it be used for malaria control? Am J Trop Med Hyg (2007) 1.74
In vitro activities of piperaquine and other 4-aminoquinolines against clinical isolates of Plasmodium falciparum in Cameroon. Antimicrob Agents Chemother (2003) 1.72
Short report: association between chloroquine and amodiaquine resistance and allelic variation in the Plasmodium falciparum multiple drug resistance 1 gene and the chloroquine resistance transporter gene in isolates from the upper Nile in southern Sudan. Am J Trop Med Hyg (2003) 1.72
Amodiaquine for treating malaria. Cochrane Database Syst Rev (2003) 1.71
Fixed-dose pyronaridine-artesunate combination for treatment of uncomplicated falciparum malaria in pediatric patients in Gabon. J Infect Dis (2008) 1.70
Monitoring and deterring drug-resistant malaria in the era of combination therapy. Am J Trop Med Hyg (2007) 1.69
Reaction of antimalarial endoperoxides with specific parasite proteins. Antimicrob Agents Chemother (1994) 1.68
Intensity of malaria transmission and the evolution of drug resistance. Acta Trop (2005) 1.66
Focusing on quality patient care in the new global subsidy for malaria medicines. PLoS Med (2009) 1.63
The clay feet of the malaria giant and its African roots: hypotheses and inferences about origin, spread and control of Plasmodium falciparum. Parassitologia (1999) 1.63
The antimalarial action on Plasmodium falciparum of qinghaosu and artesunate in combination with agents which modulate oxidant stress. Trans R Soc Trop Med Hyg (1987) 1.63
Artemisinin antimalarials in pregnancy: a prospective treatment study of 539 episodes of multidrug-resistant Plasmodium falciparum. Clin Infect Dis (2001) 1.62
Genetic linkage of pfmdr1 with food vacuolar solute import in Plasmodium falciparum. EMBO J (2006) 1.58
Clinical pharmacology of artemisinin-based combination therapies. Clin Pharmacokinet (2008) 1.54
Recent highlights in antimalarial drug resistance and chemotherapy research. Trends Parasitol (2008) 1.52
Advances in understanding the genetic basis of antimalarial drug resistance. Curr Opin Microbiol (2007) 1.50
In vitro monitoring of Plasmodium falciparum drug resistance in French Guiana: a synopsis of continuous assessment from 1994 to 2005. Antimicrob Agents Chemother (2007) 1.49
Antimalarial drugs: recent advances in molecular determinants of resistance and their clinical significance. Cell Mol Life Sci (2006) 1.42
Bisquinolines. 1. N,N-bis(7-chloroquinolin-4-yl)alkanediamines with potential against chloroquine-resistant malaria. J Med Chem (1992) 1.40
Intensity of malaria transmission and the spread of Plasmodium falciparum resistant malaria: a review of epidemiologic field evidence. Am J Trop Med Hyg (2007) 1.39
Artemisinin and a series of novel endoperoxide antimalarials exert early effects on digestive vacuole morphology. Antimicrob Agents Chemother (2007) 1.37
A network to monitor antimalarial drug resistance: a plan for moving forward. Trends Parasitol (2007) 1.37
Supervised versus unsupervised antimalarial treatment with six-dose artemether-lumefantrine: pharmacokinetic and dosage-related findings from a clinical trial in Uganda. Malar J (2006) 1.37
Ferriprotoporphyrin IX, phospholipids, and the antimalarial actions of quinoline drugs. Life Sci (2004) 1.37
Malaria: progress, perils, and prospects for eradication. J Clin Invest (2008) 6.54
Chloroquine resistance in Plasmodium falciparum malaria parasites conferred by pfcrt mutations. Science (2002) 6.19
Spiroindolones, a potent compound class for the treatment of malaria. Science (2010) 5.94
pfmdr1 mutations contribute to quinine resistance and enhance mefloquine and artemisinin sensitivity in Plasmodium falciparum. Mol Microbiol (2005) 4.92
Decreasing pfmdr1 copy number in plasmodium falciparum malaria heightens susceptibility to mefloquine, lumefantrine, halofantrine, quinine, and artemisinin. J Infect Dis (2006) 4.21
Efficient site-specific integration in Plasmodium falciparum chromosomes mediated by mycobacteriophage Bxb1 integrase. Nat Methods (2006) 3.32
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. Science (2011) 3.30
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery. Science (2011) 3.07
The fatty acid biosynthesis enzyme FabI plays a key role in the development of liver-stage malarial parasites. Cell Host Microbe (2008) 2.98
Quantitative assessment of Plasmodium falciparum sexual development reveals potent transmission-blocking activity by methylene blue. Proc Natl Acad Sci U S A (2011) 2.83
In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with artemether-lumefantrine in Africa. J Infect Dis (2009) 2.80
Alternative mutations at position 76 of the vacuolar transmembrane protein PfCRT are associated with chloroquine resistance and unique stereospecific quinine and quinidine responses in Plasmodium falciparum. Mol Pharmacol (2002) 2.57
Use of high-density tiling microarrays to identify mutations globally and elucidate mechanisms of drug resistance in Plasmodium falciparum. Genome Biol (2009) 2.23
Gene encoding a deubiquitinating enzyme is mutated in artesunate- and chloroquine-resistant rodent malaria parasites. Mol Microbiol (2007) 2.18
Transporters involved in resistance to antimalarial drugs. Trends Pharmacol Sci (2006) 2.09
A critical role for PfCRT K76T in Plasmodium falciparum verapamil-reversible chloroquine resistance. EMBO J (2005) 2.09
Evidence for a central role for PfCRT in conferring Plasmodium falciparum resistance to diverse antimalarial agents. Mol Cell (2004) 2.02
Targeting tuberculosis and malaria through inhibition of Enoyl reductase: compound activity and structural data. J Biol Chem (2003) 1.81
Drug resistance-associated pfCRT mutations confer decreased Plasmodium falciparum digestive vacuolar pH. Mol Biochem Parasitol (2004) 1.79
Site-specific genome editing in Plasmodium falciparum using engineered zinc-finger nucleases. Nat Methods (2012) 1.79
Identification of a mutant PfCRT-mediated chloroquine tolerance phenotype in Plasmodium falciparum. PLoS Pathog (2010) 1.71
Recent clinical and molecular insights into emerging artemisinin resistance in Plasmodium falciparum. Curr Opin Infect Dis (2011) 1.68
Piperaquine resistance is associated with a copy number variation on chromosome 5 in drug-pressured Plasmodium falciparum parasites. Antimicrob Agents Chemother (2011) 1.67
In vitro efficacy, resistance selection, and structural modeling studies implicate the malarial parasite apicoplast as the target of azithromycin. J Biol Chem (2006) 1.65
Defining the role of PfCRT in Plasmodium falciparum chloroquine resistance. Mol Microbiol (2005) 1.64
Structural elucidation of the specificity of the antibacterial agent triclosan for malarial enoyl acyl carrier protein reductase. J Biol Chem (2002) 1.63
PfCRT and its role in antimalarial drug resistance. Trends Parasitol (2012) 1.63
Genetic linkage of pfmdr1 with food vacuolar solute import in Plasmodium falciparum. EMBO J (2006) 1.58
Mitotic evolution of Plasmodium falciparum shows a stable core genome but recombination in antigen families. PLoS Genet (2013) 1.54
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum. Nat Chem Biol (2009) 1.52
Advances in understanding the genetic basis of antimalarial drug resistance. Curr Opin Microbiol (2007) 1.50
Chloroquine resistance modulated in vitro by expression levels of the Plasmodium falciparum chloroquine resistance transporter. J Biol Chem (2003) 1.48
In vitro evaluations of antimalarial drugs and their relevance to clinical outcomes. Int J Parasitol (2008) 1.45
Drug discovery: Priming the antimalarial pipeline. Nature (2010) 1.40
PfCRT and the trans-vacuolar proton electrochemical gradient: regulating the access of chloroquine to ferriprotoporphyrin IX. Mol Microbiol (2006) 1.33
Identifying apicoplast-targeting antimalarials using high-throughput compatible approaches. FASEB J (2011) 1.31
Genetic disruption of the Plasmodium falciparum digestive vacuole plasmepsins demonstrates their functional redundancy. J Biol Chem (2004) 1.25
Probing the multifactorial basis of Plasmodium falciparum quinine resistance: evidence for a strain-specific contribution of the sodium-proton exchanger PfNHE. Mol Biochem Parasitol (2009) 1.20
Evidence for a pfcrt-associated chloroquine efflux system in the human malarial parasite Plasmodium falciparum. Biochemistry (2005) 1.20
Plasmodium falciparum Sec24 marks transitional ER that exports a model cargo via a diacidic motif. Mol Microbiol (2008) 1.19
Identification of MMV malaria box inhibitors of plasmodium falciparum early-stage gametocytes using a luciferase-based high-throughput assay. Antimicrob Agents Chemother (2013) 1.18
Investigations into the role of the Plasmodium falciparum SERCA (PfATP6) L263E mutation in artemisinin action and resistance. Antimicrob Agents Chemother (2010) 1.14
Diversity-Oriented Synthesis Yields a Novel Lead for the Treatment of Malaria. ACS Med Chem Lett (2011) 1.12
Evidence that mutant PfCRT facilitates the transmission to mosquitoes of chloroquine-treated Plasmodium gametocytes. J Infect Dis (2011) 1.10
Transfusion of stored blood impairs host defenses against Gram-negative pathogens in mice. Transfusion (2014) 1.09
Disruption of a Plasmodium falciparum gene linked to male sexual development causes early arrest in gametocytogenesis. Proc Natl Acad Sci U S A (2005) 1.08
X-ray structural analysis of Plasmodium falciparum enoyl acyl carrier protein reductase as a pathway toward the optimization of triclosan antimalarial efficacy. J Biol Chem (2007) 1.07
First evidence of pfcrt mutant Plasmodium falciparum in Madagascar. Trans R Soc Trop Med Hyg (2006) 1.07
Select pyrimidinones inhibit the propagation of the malarial parasite, Plasmodium falciparum. Bioorg Med Chem (2009) 1.07
Using genetic methods to define the targets of compounds with antimalarial activity. J Med Chem (2013) 1.06
A method for rapid genetic integration into Plasmodium falciparum utilizing mycobacteriophage Bxb1 integrase. Methods Mol Biol (2010) 1.04
Synthesis, biological activity, and X-ray crystal structural analysis of diaryl ether inhibitors of malarial enoyl acyl carrier protein reductase. Part 1: 4'-substituted triclosan derivatives. Bioorg Med Chem Lett (2005) 1.02
Effects on growth, hemoglobin metabolism and paralogous gene expression resulting from disruption of genes encoding the digestive vacuole plasmepsins of Plasmodium falciparum. Int J Parasitol (2006) 1.01
Malaria's missing number: calculating the human component of R0 by a within-host mechanistic model of Plasmodium falciparum infection and transmission. PLoS Comput Biol (2013) 0.99
In vivo and in vitro antimalarial properties of azithromycin-chloroquine combinations that include the resistance reversal agent amlodipine. Antimicrob Agents Chemother (2011) 0.99
Type II fatty acid biosynthesis is essential for Plasmodium falciparum sporozoite development in the midgut of Anopheles mosquitoes. Eukaryot Cell (2013) 0.98
Role of Plasmodium falciparum digestive vacuole plasmepsins in the specificity and antimalarial mode of action of cysteine and aspartic protease inhibitors. Antimicrob Agents Chemother (2009) 0.98
Differences in trans-stimulated chloroquine efflux kinetics are linked to PfCRT in Plasmodium falciparum. Mol Microbiol (2007) 0.98
Oleic acid biosynthesis in Plasmodium falciparum: characterization of the stearoyl-CoA desaturase and investigation as a potential therapeutic target. PLoS One (2009) 0.98
Synthesis and biological activity of diaryl ether inhibitors of malarial enoyl acyl carrier protein reductase. Part 2: 2'-substituted triclosan derivatives. Bioorg Med Chem Lett (2006) 0.94
Characterization of a PRL protein tyrosine phosphatase from Plasmodium falciparum. Mol Biochem Parasitol (2007) 0.93
Spatial and temporal mapping of the PfEMP1 export pathway in Plasmodium falciparum. Cell Microbiol (2013) 0.93
Chloroquine-resistant isoforms of the Plasmodium falciparum chloroquine resistance transporter acidify lysosomal pH in HEK293 cells more than chloroquine-sensitive isoforms. Mol Biochem Parasitol (2006) 0.92
Discovery of novel inhibitors targeting enoyl-acyl carrier protein reductase in Plasmodium falciparum by structure-based virtual screening. Biochem Biophys Res Commun (2007) 0.92
Degrees of chloroquine resistance in Plasmodium - is the redox system involved? Int J Parasitol Drugs Drug Resist (2012) 0.89
A ubiquitous Plasmodium protein displays a unique surface labeling pattern in sporozoites. Mol Biochem Parasitol (2006) 0.89
Multicolor bioluminescence boosts malaria research: quantitative dual-color assay and single-cell imaging in Plasmodium falciparum parasites. Anal Chem (2014) 0.88
Plasmodium falciparum phosphoethanolamine methyltransferase is essential for malaria transmission. Proc Natl Acad Sci U S A (2013) 0.87
Identification of a role for the PfEMP1 semi-conserved head structure in protein trafficking to the surface of Plasmodium falciparum infected red blood cells. Cell Microbiol (2010) 0.86
Quinine dimers are potent inhibitors of the Plasmodium falciparum chloroquine resistance transporter and are active against quinoline-resistant P. falciparum. ACS Chem Biol (2014) 0.86
A var gene promoter implicated in severe malaria nucleates silencing and is regulated by 3' untranslated region and intronic cis-elements. Int J Parasitol (2009) 0.85
Perspectives: The missing pieces. Nature (2012) 0.84
Tricks in Plasmodium's molecular repertoire--escaping 3'UTR excision-based conditional silencing of the chloroquine resistance transporter gene. Int J Parasitol (2012) 0.83
An integrated strategy for efficient vector construction and multi-gene expression in Plasmodium falciparum. Malar J (2013) 0.83
Differential drug efflux or accumulation does not explain variation in the chloroquine response of Plasmodium falciparum strains expressing the same isoform of mutant PfCRT. Antimicrob Agents Chemother (2011) 0.83
Loss of malarial susceptibility to artemisinin in Thailand. Lancet (2012) 0.83
Mutations conferring drug resistance in malaria parasite drug transporters Pgh1 and PfCRT do not affect steady-state vacuolar Ca2+. Antimicrob Agents Chemother (2005) 0.82
N-aryl-2-aminobenzimidazoles: novel, efficacious, antimalarial lead compounds. J Med Chem (2014) 0.82
In vitro and in vivo activity of solithromycin (CEM-101) against Plasmodium species. Antimicrob Agents Chemother (2011) 0.81
Novel diaryl ureas with efficacy in a mouse model of malaria. Bioorg Med Chem Lett (2012) 0.79
Evidence for pyronaridine as a highly effective partner drug for treatment of artemisinin-resistant malaria in a rodent model. Antimicrob Agents Chemother (2013) 0.79
UV-triggered affinity capture identifies interactions between the Plasmodium falciparum multidrug resistance protein 1 (PfMDR1) and antimalarial agents in live parasitized cells. J Biol Chem (2013) 0.79
Triclosan is minimally effective in rodent malaria models. Nat Med (2011) 0.79
Yeast-based high-throughput screen identifies Plasmodium falciparum equilibrative nucleoside transporter 1 inhibitors that kill malaria parasites. ACS Chem Biol (2015) 0.79
No evidence of decreased artemisinin efficacy in a high-transmission malaria setting in Mali. Am J Trop Med Hyg (2012) 0.78
The longin domain regulates the steady-state dynamics of Sec22 in Plasmodium falciparum. Eukaryot Cell (2009) 0.78
Recent insights into fatty acid acquisition and metabolism in malarial parasites. F1000 Biol Rep (2010) 0.77
Discrimination of potent inhibitors of Toxoplasma gondii enoyl-acyl carrier protein reductase by a thermal shift assay. Biochemistry (2013) 0.77
Corrigendum: A novel multiple-stage antimalarial agent that inhibits protein synthesis. Nature (2016) 0.77
Arresting malaria parasite egress from infected red blood cells. Nat Chem Biol (2008) 0.77
Taking Charge: Feeding Malaria via Anion Channels. Cell (2011) 0.75